Cite
HARVARD Citation
Vledder, A. et al. (n.d.). 2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial. International journal of gynecological cancer. p. A304. [Online].